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II. Abbreviation List 
°C Degree Celsius 
% Percentage 
αSMA α-smooth muscle actin 
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cpPSCs Chronic pancreatitis-associated pancreatic stellate cells 
CP Chronic pancreatitis 
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ELISA Enzyme-Linked ImmunoSorbent Assay 
EMT Epithelial-mesenchymal transition 
FAK/β1 integrin β1 integrin-focal adhesion kinase signaling 
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Gly Glycine 
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GTEx Genotype-tissue expression  
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HA hyaluronic acid 
HSCs Hepatic stellate cells 





mAb Monoclonal antibody 







NEAA Non-essential amino acids  
nm Nanometer 
nM Nanomolar 
nPSCs Normal pancreatic stellate cells 
OS Overall survival 
OSCC Oral squamous cell carcinoma cells 
PAGE Polyacrylamide gel electrophoresis  
PBS Phosphate-buffered saline 
PCN Penicillin 
PCCs Pancreatic cancer cells 
PDAC Pancreatic ductal adenocarcinoma 
PDGF Platelet derived growth factor 
PFS Progression-free survival 
PSCs Pancreatic stellate cells 
qRT-PCR Quantitative real-time polymerase chain reaction 
rTHBS1 Recombinant Thrombospondin 1 
RT Room temperature 
s Second 
SD Standard deviation 




SDF-1 Stromal cell-derived factor 1 
SHH Sonic hedgehog 
SSc Systemic sclerosis 
STAT3 Signal transducer and activator of transcription 3 
STR Streptomycin 
Tregs T regulatory cells 
TAMs Tumor-associated macrophages 
Th2 T helper type 2 
TCA Tricarboxylic acid 
TCGA The cancer genome atlas 
THBS1 Thrombospondin 1 
TGF-β1 Transforming growth factor-β1 
TME Tumor microenvironment 
TNF-α Tumor necrosis factor-α 
VD Vitamin D3 
VDR Vitamin D3 receptor 
V Volt 
VEGF Vascular endothelial growth factor 
WB Western blot 








Pancreatic cancer is one of the deadliest gastrointestinal cancers with dismal clinical 
outcomes worldwide [1], and the majority of pancreatic cancer (around 85%) is 
pancreatic ductal adenocarcinoma (PDAC) [2, 3]. PDAC is characterized by the severe 
stromal/desmoplastic reaction in the tumor microenvironment (TME) [4-6]. Many 
studies have proved that the activated pancreatic stellate cells (PSCs) induce this 
profibrotic reaction in PDAC by modulating the production of extracellular matrix (ECM) 
proteins and other molecules in TME. Additionally, the interaction among PSCs, cancer 
cells and other stromal cells contributes to a tumor-supportive TME, thereby increasing 
the aggressiveness of PDAC through several signaling pathways. Recently, PSCs-
targeted strategies have become promising for PDAC therapy, and several stroma-
targeting strategies have been proposed [6, 7]. Among the proposed strategies, 
ligands of Vitamin D receptor (VDR) have emerged as a promising treatment since 











1.1 Epidemiology of pancreatic cancer 
Based on data from the International Agency for Research on Cancer's GLOBOCAN, 
pancreatic cancer is the 11th most common cancer with 458,918 new cases and the 7th 
major cause of cancer-related deaths with 432,242 deaths globally in 2018 [13].  
There are significant differences in age-standardized incidence rates (ASIR) and 
mortality rates (ASMR) among different areas, as indicated in Figure 1 [13, 14]. ASIR 
of pancreatic cancer is much higher in developed countries. Europe (7.7 per 100,000) 
and North America (7.6 per 100,000) show the highest ASIR of pancreatic cancer, while 
Africa (2.2 per 100,000) and South-Central Asia (<2.0 per 100,000) have the lowest 
ASIR [13, 15]. In addition, men have a higher ASIR of pancreatic cancer than women 
worldwide since pancreatic cancer is the 12th most common cancer in men and the 11th 
in women [13]. 
Although people are becoming more aware of pancreatic cancer risk factors and have 
developed novel tools for early diagnosis, the incidence of pancreatic cancer has 
climbed in recent years and is projected to rise continuously. It is estimated that there 
will be 355,317 new diagnoses of pancreatic cancer until 2040 [13]. In addition, 
pancreatic cancer is expected to overtake breast cancer soon in the European Union 






Figure 1: Maps of ASIR (up) and ASMR (down) of pancreatic cancer worldwide in 2018 









1.2 Major cellular players in PDAC-TME 
In the past few decades, scientists have revealed the critical role of TME in PDAC 
progression. TME means the crosstalk between PCCs and their surroundings, 
establishing a complex tumor-supportive environment for the development of PDAC. 
The fibrotic TME can provide a protective barrier for chemotherapy treatment and 
contribute to epithelial to mesenchymal transition (EMT), and allow PCCs to spread to 
adjacent tissues [17]. This procedure includes continuous stromal reprogramming and 
the activation of various pathways in PDAC-TME [18, 19]. The following parts will 
introduce some of the main cellular components of TME. 
1.2.1 PSCs 
Stellate cells were first discovered in the liver by the German anatomist Karl Wilhelm 
von Kupffer and described in a research letter in 1876 [20]. Nearly one century later, 
Wateari et al. identified similar star-shaped cells (later known as PSCs) with Vitamin A 
storage in mouse pancreas [21]. However, the field of PSCs didn't receive great 
attention until two landmark articles outlined the in vitro isolation and culture methods 
of PSCs in 1998 [22, 23]. With the great efforts made by many scientists, PSCs are 
well recognized as the significant component of fibrosis in pancreatic diseases such 
as chronic pancreatitis (CP) and PDAC [4, 24-26].  
In health, PSCs are in a quiescent status (qPSCs) with numerous lipid droplets and 
can be found in the peri-acinar areas [22, 23]. qPSCs comprise around 4% of the local 
cells in the pancreas [27] and participate in the vitamin A storage, immunity, normal 
exocrine and endocrine secretion, and the maintenance of normal architecture of the 
pancreas [28]. Desmin, glial fibrillary acidic protein, vimentin, nestin, nerve growth 




In PDAC and CP, qPSCs are continuously stimulated and transform into an activated 
state [29, 30]. During the transformation, PSCs change the morphology and function 
as follows: a) a myofibroblasts-like shape and loss of the vitamin A-rich lipid droplets; 
b) positive expression of α-smooth muscle actin (αSMA); c) upregulated secretion of 
various factors; d) increased migration and proliferation; e) elevated release of ECM 
components such as collagens, laminin, hyaluronic acid (HA) and fibronectin [29, 30]. 
In addition, the interaction of PSCs, PCCs, and other stromal cells plays a vital role in 
immune tolerance, chemoresistance, angiogenesis, metastasis, and recurrence of 
PDAC.  
1.2.2 Myeloid-derived suppressor cells (MDSCs) 
MDSCs are defined as immature bone marrow-derived cells exerting a vital role in the 
immunosuppression of PDAC. MDSCs can be induced by PCCs to mobilize from the 
bone marrow, enter the systemic circulation, and then be recruited to TME [31]. Diaz-
Montero et al. indicated that the amount of MDSCs in the peripheral blood was closely 
related to the clinical cancer stage and metastatic tumor burden in PDAC patients [32]. 
With the growth of tumor and the generation of TME-hypoxia, hypoxia-inducible factors 
are increased and become the crucial factors of recruiting MDSC into PDAC-TME [33]. 
In TME, MDSCs-released reactive oxygen species were reported to suppress T cell 
responses, showing an immunosuppressive function [34]. In addition, Pinton et al. 
reported that the crosstalk between MDSCs and T cells could induce the 
immunosuppression of MDSCs [35]. MDSCs secreted the programmed death protein 
ligand-1, upregulated by T cells-secreted interleukin (IL)-10, could cause T cell 
dysfunction [35]. MDSCs-secreted IL-10 and transforming growth factor-β (TGF-β) 
enhanced the proliferation of T regulatory cells (Tregs), mediating the 




Evidence also showed that hypoxia could induce the differentiation of MDSCs into 
Tumor-associated macrophages (TAMs), another critical cell type in TME, by 
upregulating CD45 phosphatase and downregulating signal transducer and activator 
of transcription 3 (STAT3) [37].  
1.2.3 TAMs 
As an essential cell type in the TME, macrophages display significant plasticity allowing 
them to perform multiple functions in the tumor progression. Macrophages can 
differentiate to M1 or M2 phenotypes. M1-type macrophages take part in the formation 
of inflammatory and fibrotic TME in the early stages. In contrast, M2-type macrophages 
(known as TAMs) observed in the later stages of PDAC development can induce 
immunosuppression of PCCs and increase tumor malignancy [38, 39]. Accumulating 
evidence has indicated that TAMs play an essential role in the invasion and metastasis 
of cancer cells [40-42]. In PDAC patients, the elevated count of M2-polarized TAMs is 
associated with increased lymphatic metastasis and neural invasion [43, 44]. 
Cytokines can recruit TAMs into TME, and TAMs also secret many factors which 
increase the proliferation of PCCs [45]. TAMs-released IL-10 and TGF-β can inhibit the 
anti-tumor immune response mediated by dendritic cells (DCs), thereby remodeling an 
immunosuppressive TME [46]. In addition, PCCs can induce the differentiation of 
macrophages into the M2 phenotypes by paracrine pathways [47, 48]. Liou et al. 
reported that PCCs caused the differentiation of macrophages into the M2 phenotypes 
by secreting IL-13 [47].  
Overall, both the TME's physical barrier effect and the TME-PCCs crosstalk contribute 
to the development and progression of PDAC. As one of the critical cell types in PDAC-





1.3 Role of PSCs in PDAC 
As the prominent cellular component of the PDAC-TME, PSCs have received 
enormous attention in recent decades [49-61]. Accumulating evidence has shown that 
the crosstalk among PSCs, PCCs, and other stromal cells can remodel a tumor-
supportive microenvironment of PDAC, thus enhancing tumor progression and 
chemoresistance via various pathways [62-64]. The following sections will give a 
general review of the role of PSCs in PDAC progression. Figure 2 is a graphic summary 
of the PSCs transformation and the crosstalk among PSCs, PCCs, and other stromal 
cells [65].  
 
Figure 2: Simplified graph of PSCs transformation and the interaction of PSCs, PCCs, 
and other stromal cells (adjusted based on our review in Front. Oncol [65]). PCCs 
stimulate the conversion of PSCs from quiescence to an activated state by releasing 
chemokines or cytokines. In addition, PSCs secret numerous factors that keep PSCs 




pathways. Moreover, PSCs contribute to increased angiogenesis via interacting with 
endothelial cells. PSCs also secret neurotrophic factors, leading to pain in PDAC. Furthermore, 
PSCs play an essential role in creating an immunosuppressive TME via the crosstalk with 
immune cells. bFGF: basic fibroblast growth factor; PDGF: Platelet-derived growth factor; 
VEGF: Vascular endothelial growth factor; TNF-α: tumor necrosis factor-α; MMP: Matrix 
metalloproteinase; SDF-1: stromal cell-derived factor 1. 
 
1.3.1 PSCs and TME remodeling 
PSCs-derived ECM components and molecules contribute to intratumoral hypoxia, 
EMT, angiogenesis, invasiveness, drug resistance as well as the formation of a tumor-
supportive microenvironment in PDAC [66]. Berchtold et al. indicated that PSCs 
upregulated ECM and caused a more aggressive behavior of PCCs through β1 
integrin-focal adhesion kinase (FAK/β1 integrin) signaling [67]. Di Maggio et al. 
indicated that ECM proteins got deposited and established a physical barrier that 
prevented drugs' delivery to the tumor [68]. Furthermore, deposited ECM proteins have 
been reported to augment interstitial pressure in tumors [69], closely correlated with 
vascular atrophy, hypoxia, and lack of nutrition [70].  
Interestingly, some experiments showed that PSCs were able to augment the 
malignancy of cancer cells even in the nutrient-exhausted and hypoxic 
microenvironment of PDAC via paracrine signaling pathways or genetic alterations [71, 
72]. For instance, upregulation of sonic hedgehog (SHH) induced by oncogenic KRAS 
mutations in PDAC cells can activate PSCs in the paracrine pathway. This, in turn, 
stimulates the PI3K-AKT signaling and respiratory activity in the mitochondria of cancer 
cells, thereby augmenting oxygen availability for PCCs in the hypoxic TME [73]. In 




extracellular proteins for the lysosomal-mediated catabolism, which guarantees amino 
acids recycling and fuels tumor growth [70]. Moreover, PSCs autophagy can induce 
alanine production, which fuels the tricarboxylic acid (TCA) cycle in PDAC, thereby 
promoting non-essential amino acids (NEAA) and lipid biosynthesis [72]. Zhao et al. 
found that PSCs-derived exosomes contained lots of amino acids, lipids, and TCA 
cycle intermediates, thereby fueling PCCs for central carbon metabolism, promoting 
tumor growth under nutrient-deprived TME [74].  
1.3.2 PSCs and drug resistance 
Recent findings have revealed that PSCs can influence the drug resistance of PCCs. 
PSCs show a drug-scavenging ability that entraps active gemcitabine (GEM) within 
the stroma, making GEM unavailable for cancer cells [75]. Buckway et al. indicated 
that hyaluronidase treatment could enhance the penetration of chemotherapy drugs 
by breaking down the stromal barrier in tumor-bearing mice [76].  
Furthermore, PSCs can produce various factors which enhance the resistance to drugs 
in PDAC [52, 70, 77]. Several studies have explored the function of PSCs in the 
therapeutic resistance of PDAC. Liu et al. found that PSCs-derived periostin kept the 
continuous activation state of PSCs, increased drug resistance to GEM, and promoted 
the aggressiveness of PCCs through ERK1/2 and FAK/AKT signaling [78]. Singh et al. 
reported that SDF-1 released by PSCs could increase the chemoresistance of PCCs 
via its receptor CXCR4 on cancer cells [79]. Additionally, PSCs-derived SDF-1α was 
reported to increase drug resistance to GEM through ERK1/2 and FAK/AKT pathways 
in PCCs [80]. Amrutkar et al. reported that PSCs-secreted fibronectin augmented the 
drug resistance of PCCs through ERK1/2 signaling [81]. Furthermore, Richards et al. 
showed that exosomes secreted by PSCs caused GEM resistance in cancer cells by 




1.3.3 PSCs in PDAC metastasis   
PSCs and PSCs-derived factors have been proved to play a critical role in PDAC 
metastasis. PSCs were shown to stimulate the EMT process in PCCs, a recognized 
process of initiation of PDAC metastasis [83, 84]. Neesse et al. showed that PSCs 
augmented the invasiveness of serine protease inhibitor nexin2 (SERPINE2)-
expressing PCCs in PDAC xenograft tumors [85]. The investigations by Tian et al. 
indicated that PCCs could be induced into a more invasive phenotype by the binding 
of PCC-derived fibroblast growth factor (FGF) to its receptor on PSCs [86].  
PSCs can also migrate to metastatic sites together with PCCs, forming a niche for the 
metastasis of PDAC. A hallmark study by Xu et al. indicated that PSCs from the primary 
tumor area could be even detected and further lead to a severe stromal reaction in the 
distant metastatic nodules, thereby creating a metastasis-supportive TME [87]. 
Suetsugu et al. found that after splenic injection of PSCs and PCCs, both types of cells 
were observed in metastatic sites by tracking PSCs expressing green fluorescence 
protein (GFP) [88]. All these findings further support the "seed and soil" theory 
regarding cancer metastasis, which was first proposed in 1889 [89]. Therefore, a 
recent review by Pang et al. recommended testing circulating PSCs together with 
circulating tumor cells as potential biomarkers in PDAC [90]. 
In addition, PSCs-secreted molecules have been shown to contribute to PDAC 
metastasis. SDF [91], galectin-3 [92], hepatocyte growth factor (HGF) [93], IL-6) [94], 
thrombospondin-2 [95], matrix metallopeptidase 2 (MMP2) [96] and nerve growth 
factor (NGF) [97] have been well proved to drive the metastasis of PDAC. A recent 
study by Schnittert et al. indicated that integrin α11 was upregulated in PSCs activation 
and increased PDAC metastasis [98]. Another study by Qian and his colleagues 




PCCs by paracrine SDF-1 [99]. Apte's team revealed that PSCs-secreted HGF 
enhanced the aggressiveness of PDAC via its receptor c-MET on cancer cells, and 
HGF inhibition resulted in a significant reduction of metastasis in a mouse model of 
PDAC [100, 101]. As such, PSCs and PSCs-secreted factors need more attention in 
the future development of therapeutics for PDAC.  
1.3.4 PSCs and immune suppression 
PDAC is also characterized by the evasion of host immune surveillance, and several 
studies have indicated that PSCs also play a significant role in this process [102-105]. 
Ene-Obong et al. demonstrated that PSCs-derived SDF-1 showed a chemotactic effect 
on CD8+ T cells, thereby hampering their infiltration into tumor areas [106]. Wu et al. 
indicated that PSCs upregulated the secretion of TGF-β1 and IL-10, which exposed 
inhibitory impacts on DCs and led to immune suppression in pancreatic cancer [107]. 
Furthermore, two studies demonstrated that PSCs induced the differentiation and 
expansion of MDSCs by the IL-6/STAT-3 pathway, thus creating an immunotherapy-
resistant microenvironment [70, 108]. The work by Tang et al. revealed that PSCs-
secreted galectin-1 impeded the activation of T cells, induced their apoptosis, and 
increased the secretion of T helper type 2 (Th2), thus forming an immunosuppressive 
TME of PDAC [102]. Lunardi et al. demonstrated that PSCs-secreted IL-10 improved 
recruitment of CXCR3+ Tregs and reduced cytolysis intermediated by T-cells and NK-
cells, thereby causing the immunosuppressive and tumor-promoting effects [109].  
Overall, PSCs play a vital role in the immune response against PDAC by various 
pathways. Restoring the immune reaction against PCCs by targeting PSCs is 




1.3.5 PSCs and angiogenesis in PDAC 
In PDAC, PSCs can secret many pro-angiogenic factors, such as VEGF, bFGF, IL-8, 
PDGF, and periostin, which promote proliferation, survival, and migration of endothelial 
cells, thereby contributing to angiogenesis [110]. Tang et al. found that prokineticin (PK) 
secreted by aPSCs promoted angiogenesis by inducing the function of the PK/PKR 
system on endothelial cells [110]. Kuninty et al. showed that TGF-β-activated PSCs 
induced tube formation (a measure of angiogenesis) of endothelial cells, which could 
be regulated via the therapeutic miRNA-199a-3p and miRNA-214-3p [111]. Patel et al. 
showed that PSCs increased proliferation and tube formation of microvascular 
endothelial cells via the HGF/c-Met pathway [112]. 
1.3.6 PSCs and nerve interaction in PDAC 
PSCs are also involved in neural invasion in PDAC. Li et al. demonstrated that 
activated PSCs induced neurite outgrowth towards PCCs and promoted the neural 
invasion of PCCs [113]. More recently, Nan et al. reported that PSCs promoted the 
perineural invasion of PCCs via the HGF/c-Met pathway [59]. In addition, Han et al. 
reported that PSCs contributed to pain in PDAC by PSCs-induced secretion of pain 
factors from dorsal root ganglia [114]. Demir et al. also found that conditioned medium 
(CM) from cancer-associated PSCs could stimulate neuron outgrowth [115]. 
In summary, PSCs contribute to the severe stromal/desmoplastic reaction in PDAC-
TME. In addition, the PSCs-PCCs paracrine crosstalk remodels a tumor-supportive 
stroma which increases the malignancy of cancer cells. Recently, targeting PSCs has 
emerged as a promising strategy for PDAC therapy, and several targeted therapies 





1.4 Therapeutic strategies targeting PSCs 
Due to the increasingly recognized role of the PSCs in PDAC progression, some 
approaches to modulate the tumor stroma have been developed [51, 78, 99, 111, 116-
118]. Among these strategies, simple PSCs depletion was shown to cause more 
aggressive tumors with decreased survival in the transgenic mouse model of PDAC 
[119]. Consequently, recent studies have focused on normalizing PSCs or reducing 
ECM directly [120-123]. Figure 3 is a schematic diagram of the leading strategies, and 
the following sections will review several novel promising approaches. 
 
Figure 3: Principal strategies for PSCs-directed PDAC treatment. Two main strategies 
targeting PSCs or ECM as PDAC treatment are discussed. To begin with, PSCs can be 
normalized into an inactive phenotype by utilizing molecules like ATRA or calcipotriol (Cal). In 





i) SHH pathway inhibitors  
PCCs have been shown to accelerate the stromal reaction via the paracrine SHH 
pathway [114]. Experiments on inhibiting SHH signaling showed different results. 
Oliver et al. demonstrated that a combination of IPI-926 (a hedgehog inhibitor) and 
GEM enhanced the intratumoral vascular density and GEM delivery to the tumor [124]. 
Nevertheless, Rhim and his colleagues indicated that PDAC mice with SHH deletion 
displayed more aggressive and undifferentiated tumors than controls [125]. Hence, the 
phase II clinical trial based on IPI-926 was canceled on account of elevated mortality 
[126]. Hwang et al. indicated that AZD8542 (a novel hedgehog inhibitor) decreased 
tumor volume and metastasis in an orthotopic model of PDAC [127]. 
ii) Vitamin A analogs 
Vitamin A analogs show an ability to normalize PSCs. For instance, after treatment of 
PSCs with all-trans retinoic acid (ATRA), activation of PSCs was prevented, resulting 
in less aggressiveness of PCCs by paracrine signaling [123, 128, 129]. Moreover, Han 
et al. demonstrated that gold nanoparticles containing ATRA and heat-shock protein 
47 siRNA normalized PSCs, resulting in increased intratumoral GEM concentration 
[130]. Nevertheless, several clinical trials with vitamin A analogs exhibited 
unsatisfactory results. Michael et al. showed that combination therapy with GEM and 
13-cis-retinoic acid (13-cis-RA) could not improve the response rate in PDAC patients 
[131]. Moore et al. indicated that combination therapy (13-cis-RA+interferon-α) was not 
able to exhibit objective anti-cancer activity in PDAC patients [132]. Recently, another 
trial (NCT03307148) repurposing ATRA as a stromal targeting agent along with GEM 
plus nab-paclitaxel for PDAC is underway, and its phase Ib trial (NCT03307148) has 
shown that ATRA+GEM+nab-paclitaxel treatment in advanced, unresectable PDAC 




iii) Angiotensin II (Ang-II) Inhibitors 
Two Ang-II inhibitors (olmesartan) have been investigated since Ang-II is able to 
increase the proliferation of PSCs via protein kinase C and EGF/ERK signaling [134]. 
Masamune et al. showed that Olmesartan could decrease proliferation and collagen I 
synthesis by PSCs, thereby reducing carcinoma growth in vivo [135]. Another study by 
Chauhan et al. indicated that losartan reduced intratumoral pressure and 
decompressed tumor blood vessels, which increased drug delivery and oxygen 
delivery to tumors in orthotopic PDAC mice [136]. 
iv) Pirfenidone 
Pirfenidone, an antifibrotic agent for treating idiopathic pulmonary fibrosis, was 
reported to deactivate PSCs and decrease the production of collagen and periostin, 
thus reducing proliferation and invasion of pancreatic cancer cells in vivo [137]. Kozono 
et al. showed that combination therapy (pirfenidone+GEM) normalized PSCs and 
reduced the production of collagen, thereby decreasing tumor growth and liver 
metastasis in an orthotopic model of PDAC [137]. Suklabaidya et al. indicated that 
combination strategy (pirfenidone+N-acetyl cysteine) decreased desmoplasia as well 
as the growth and metastasis of tumor in an orthotopic hamster model of PDAC [138]. 
v) miRNA-based approaches 
Recently, researchers have also tried to modulate PSCs with miRNA [139]. Kwon et al. 
showed that miRNA-29 was decreased when PSCs got activated, and overexpression 
of miRNA-29 in PSCs decreased invasiveness of PCCs in co-culture [140]. Asama et 
al. revealed that miRNA let-7d showed an anti-fibrosis effect by deactivating PSCs 




vi) Lipoxin A4 (LXA4) 
Schnittert et al. unraveled that endogenous lipid LXA4 was able to inhibit pancreatic 
fibrosis by deactivating PSCs, thereby abolishing PSCs-induced tumor growth and 
invasiveness in a co-injection subcutaneous tumor model [121].  
vii) Galectin-1 
Qian et al. indicated that galectin-1 was overexpressed in PSCs, and knockdown of 
galectin-1 inhibited liver metastasis in a co-injection orthotopic PDAC model [99]. Most 
recently, Orozco et al. showed that deletion of galectin-1 resulted in decreased stromal 
activation and vascularization, improved T cell infiltration, and decreased cancer 
metastasis in a PDAC mouse model [142]. 
viii) Polyethylene glycol (PEG)ylated hyaluronidase 
Jacobetz et al. found that combination therapy with GEM and PEGPH20 (a PEGylated 
hyaluronidase) degraded stromal HA, leading to decreased intratumoral pressure, 
decompression of tumor blood vessels, increased delivery of GEM, and prolonged 
survival in a PDAC mouse model [143]. A phase Ib trial by Hingorani et al. showed that 
drug combination (PEGPH20+GEM) could prolong the overall and progression-free 
survival (OS and PFS) rates in patients with advanced PDAC [144]. Moreover, in a 
phase II trial, the largest improvement in PFS was observed in patients with HA-rich 
tumors who received the combination therapy (PEGPH20+nab-paclitaxel+GEM) [145].  
From the above, we can see that the stroma-targeted strategies have been well 
acknowledged. The strategies mainly focus on normalizing PSCs or reducing ECM 
directly have been well developed. In many diseases, Vitamin D3 (VD) analogs are 




1.5 Therapeutic potential of VD analogs in PDAC 
Given that fibrotic stroma plays a critical role in tumor aggressiveness, repurposing VD 
analogs could be of great therapeutic potential in the treatment of PDAC. 
A hallmark in vivo study by Sherman et al. revealed that VD analog reduced stromal 
fibrosis and improved the drug delivery to the PDAC tumor region [122]. Additionally, 
Kong et al. showed that VD analog reduced the release of exosomal miR-10a-5p by 
PSCs, thereby decreasing tumorigenic impacts of this oncomiRNA on PCCs [156]. 
Based on these studies, a clinical trial (NCT03520790) is currently ongoing to 
investigate the drug combination of paricalcitol, nab-paclitaxel, and GEM, in patients 
with metastatic PDAC [157]. 
Previously, our group investigated the effect of a VD analog, Cal, on the PSCs 
normalization and PSCs-induced malignancy of PCCs [158]. The effect of Cal on PSCs 
normalization was explored. Cal significantly decreased the expression of αSMA (a 
marker of activated PSCs) at mRNA and protein levels. In addition, Cal reduced the 
abilities of proliferation and migration of PSCs. These results suggested that the VD 
analog could decrease the activation of PSCs. Furthermore, Cal was able to 
significantly diminish PSCs-enhanced migration, invasion, and proliferation of PCCs, 








1.6 Aim of this study 
The overall objective of this study is to investigate the role of VDR in the PSCs-
augmented malignancy (proliferation, migration, invasion, and EMT) of PCCs. In 
addition, I will further explore which molecule is involved in this crosstalk and how that 





2. Materials and Methods 
2.1 Materials 
2.1.1 Apparatus 
Autoclave Unisteri, DE 
BD LSRFortessTM cell analyzer BD Bioscience, DE 
Centrifuge Heraeus, DE 
Cell culture incubator Binder, DE 
Cell culture incubator Thermo Fisher Scientific, USA 
Combitips Plus Sigma-Aldrich, USA 
Centrifuge Eppendorf, DE 
ChemiDoc MP Imaging System Bio-Rad, DE 
Microcentrifuge Labtech, DE 
DNA workstation Uni Equip, DE 
Drying oven Heraeus, DE 
Digital pH-Meter Knick, DE 
Ice machine KBS, DE 
Laminar flow Heraeus flow laboratoies, DE 
Liquid nitrogen tank MVE, USA 




Micro weigh Chyo, DE 
Microplate reader VERSAmax, DE 
Mini tran-blot electrophoretic transfer cell Bio-Rad, DE 
Multipette plus pipette Eppendorf, DE 
NanoDrop™ 2000/2000c spectrophotometer Thermo Fisher Scientific, USA  
Odyssey CLx LI-COR, USA 
Pipettes Sigma-Aldrich, USA 
Power supply PowerPac 300 Bio-Rad, DE 
Shaker Edmund Buehler, DE 
StepOne real-time PCR systems Applied Biosystems, DE 
Thermocycler Eppendorf, DE 
Thermomixer comfort 5355 Eppendorf, DE 
UV transilluminator Labortechnik, DE 
Vortex mixer Labnet, DE 
Waterbath Memmert, DE 
Shaking water bath  Kottermann Labortechnik, DE 
X cell II Blot module Invitrogen, DE 





2.1.2 Computer Software, hardware, and website 
Endnote X9 Clarivate Analytics, USA 
GraphPad Prism 7 GraphPad, USA 
ImageJ National Institutes of Health, USA 
SPSS statistics 21.0 IBM, USA 
Hardware HP, USA 




2.1.3 Experimental consumables 
Cell culture flasks (T25, T75, T125) Thermo Fisher Scientific, Denmark 
Corning cell scrapers Sigma-Aldrich, DE 
T.I.P.S. (10, 20, 100, 200, 1000µl) Eppendorf, DE 
Falcon cell strainer (40µm, 70µm, 100µm) BD Bioscience, USA 
15mL centrifuge tubes TPP, Switzerland 
50mL centrifuge tube Corning, Mexico 
Hyperfilm ECL GE healthcare, DE 
PVDF membrane Sigma-Aldrich, DE 




Cell culture plates (6-, 12-, 24-, 96-well) Thermo Fisher Scientific, Denmark 
Pipette (1, 5, 10, 25, 50mL) Costar, USA 
Scalpels #22 Thermo Fisher Scientific, DE 
Needles BD Bioscience, Spain 
Syringe filters (0.25, 0.45µm) Sartorius, DE 
Thick blot filter paper Bio-Rad, DE 
  
2.1.4 Chemical reagents and buffers 
Amphotericin B (AmB) solution Sigma-Aldrich, DE 
30% Acrylamide (Acr) Roth, DE 
Ammonium persulfate (APS) Serva, USA 
Bovine Serum Albumin(BSA) Biomol,DE 
Collagenase P Roche, DE 
Crystal violet Sigma-Aldrich, DE 
CaCl2·2H2O Merck, DE 
Calcipotriol (Cal) Sigma-Aldrich, DE 
D-(+)-Glucose Sigma-Aldrich, DE 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, DE 




DMEM/F12 Gibco, USA 
DNase Roche, DE 
ECLTM Western blotting system Amersham Biosciences, DE 
Ethanol (70%, 96%, >99%) Apotheke GH, DE 
Fetal bovine serum (FBS) Sigma-Aldrich, DE 
Glycine (Gly) Roth, DE 
Isopropanol Roth, DE 
KCl Serva, DE 
KH2PO4 Sigma-Aldrich, DE 
2-Mercaptoethanol Sigma-Aldrich, DE 
Mouse IgG1 Isotype Control NOVUS, DE 
MgCl2·6H2O Fluka, Switzerland 
MgSO4·7H2O Merck, DE 
Milk powder Roth, DE 
NaHCO4·2H2O Merck, DE 
NaHCO3 Sigma-Aldrich, DE 
NaCl Sigma-Aldrich, DE 
Nycodenz Axis-shield PoC, Norway 
Phosphate-buffered saline (PBS) PAN-Biotech, DE 




Pronase Roche, DE 
Standard proteins Bio-Rad, USA 
Protease inhibitor cocktail Roche, DE 
Recombinant Human THBS1 (rTHBS1) NOVUS, DE 
RPMI media 1640  Gibco, USA 
RNase-free water  Qiagen, DE 
RIPA lysis buffer, 10X Millipore, DE 
Sample buffer, 4X Bio-Rad, USA 
Sodium dodecyl sulfate (SDS) Roth, DE 
Trypan blue Sigma-Aldrich, DE 
TEMED Bio-Rad, USA 
Triton-X-100. Sigma-Aldrich, Switzerland 
Trypsin/EDTA solution Lonza, Switzerland 
Tris  Bio-Rad, USA 
Tween 20 Sigma-Aldrich, DE 
Versene Solution Gibco, USA 
  
2.1.5 Kits and Primers 




cDNA Synthesis kits Bio-Rad, USA 
Matrigel matrix Corning, DE 
QuantiTect Reverse Transcription Kit Qiagen, DE 
QuantiTect Primer Assays  Qiagen, DE 
RNeasy Micro Kit Qiagen, DE 
Transwell Inserts, Polyester membrane Corning, DE 
EZ4U kit BI-5000 Biomedica, Austria 
Human THBS1 Quantikine ELISA Kit R&D systems, DE 
Vimentin primer Qiagen, DE 
E-cadherin primer Qiagen, DE 
N-cadherin primer Qiagen, DE 
GAPDH primer Qiagen, DE 
  
2.1.6 Antibodies 
Antibody  Source 
CD47 antibody NOVUS, DE 
GAPDH (D16H11) XP Rabbit mAb CST, DE 
Thrombospondin-1 antibody (A6.1) NOVUS, DE 
IRDye (800CW, 680RD) Secondary Ab LI-COR, USA 





2.2.1 Primary PSCs Isolation and Culture 
Activated PSCs used in this project included PSCs from PDAC tumor tissue or CP 
fibrotic tissue. These PSCs were isolated by the outgrowth approach [23] utilizing 
pancreatic tissues from PDAC or CP patients who underwent surgical resection in our 
hospital. Tissues were obtained from the Biobank of our department and had already 
been anonymized before research. The Biobank had already got the informed consent 
of the patients and ethical approvement. For the isolation of activated PSCs, tissues 
were firstly removed of adipose and connective parts and washed by PBS. Tissues 
were then cut into small pieces (0.5-1mm3). Subsequently, tissue pieces were 
cultivated in 6-well plates (around 5-10 fragments/well). DMEM/F12, including 20% 
FBS, was used as the culture medium, and the formula could be found in Table 1. The 
plates containing tissue fragments were maintained in an incubator under standard 
culture conditions (37°C, 5% CO2/air, humid environment), and the media was 
renewed after 24h. After 3-5 days, activated PSCs grew from the edge of tissue 
fragments and could be observed under a light microscope. After PSCs reached a 
confluence of around 20%, tissue pieces were then removed, and the medium was 
refreshed twice a week. PSCs were collected and kept in a liquid nitrogen tank after 
they reached an 80% confluence. 
qPSCs were isolated via the method called density gradient centrifugation created by 
Apte's team [22, 159]. Briefly, adjacent normal pancreas tissues were obtained from 
patients with pancreatic diseases who underwent surgical resection in our hospital. 
Following the elimination of adipose and connective parts, the tissues were sliced into 
fragments. Then, 20mL enzyme solution and 20µL DNase solution (formula in Table 1) 




a cell strainer (100µm) was used to filter the solution, and the GBSS+NaCl solution 
(Table 1) was used to wash the nylon mesh twice. The 9.5mL BSA solution and 8mL 
Nycodenz solution were utilized to resuspend cells (Table 1). After a 20min 
centrifugation (1400g, 4°C), the fuzzy band containing qPSCs could be observed at 
the interface of the BSA and Nycodenz solutions mentioned above. This band was 
then harvested and kept in the DMEM/F12, including 20% FBS in the incubator (37°C, 
5% CO2/air, humid environment). Finally, PSCs were harvested for further experiments 
or stored in a liquid nitrogen tank after 80% confluent.  
Table 1 The formulas of different solutions involved in PSCs separation and culture 
Solutions Chemical reagents Dosage 
MgSO4  MgSO4·7H2O 700mg 
 Deionized water (DIW) 0.1L 
KH2PO4  KH2PO4 3000mg 
 DIW 0.1L 
KCl  KCl 3700mg 
 DIW 0.1L 




 DIW 0.1L 
MgCl2  MgCl2·6H2O 2100mg 
 DIW 0.1L 
CaCl2  CaCl2·2H2O 33.4mg 
 DIW 0.1L 
DNase  DNase 0.01mg 
 DIW 1mL 
GBSS+NaCl  D-(+)-Glucose 250mg 
 DIW 234.5mL 
 NaCl 1750mg 
 NaHCO3 567.5mg 
 CaCl2 solution 2.5mL 




 KCl solution 2.5mL 
 MgCl2 solution 2.5mL 
 MgSO4 solution 2.5mL 
 Na2HPO4 solution 2.5mL 
GBSS-NaCl  D-(+)-Glucose 50mg 
 DIW 47mL 
 NaHCO3 113.5mg 
 CaCl2 solution 0.5mL 
 KH2PO4 solution 0.5mL 
 KCl solution 0.5mL 
 MgCl2 solution 0.5mL 
 MgSO4 solution 0.5mL 




Enzyme  Collagenase P 26mg 
 GBSS+NaCl solution 20mL 
 Pronase  20mg 
0.3% BSA  BSA 150mg 
 GBSS+NaCl solution 50mL 
Nycodenz (28.7 %) Nycodenz 2.87g 
 GBSS-NaCl solution 10mL 
Complete medium (20%FBS) AmB 0.625mg 
 DMEM/F12 200mL 
 FBS 50mL 
 PCN 2.5x104 units 
 STR 25mg 




 DMEM/F12 180mL 
 FBS 20mL 
 PCN 2x104units 
 STR 20mg 
2.2.2 PCCs Culture 
Human pancreatic cancer cell lines (PANC-1, MIA PaCa-2, AsPC-1) were initially 
gained from ATCC company and maintained in our lab. PDAC cell lines were thawed 
and cultured with RPMI-1640 medium. PCCs were cultured in the incubator (37°C, 5% 
CO2/air, humid environment) for further experiments. 0.025% Trypsin/EDTA solution 
was used for cell dissociation. Every four months, a routine test was performed to 
check cells for mycoplasma in accordance with the internal SOPs. Once a year, cell 
authentication was conducted by IDEXX BioResearch (Ludwigsburg, Germany). 
2.2.3 qRT-PCR 
2.2.3.1 RNA extraction  
RNA extraction was conducted according to the protocol of the Qiagen RNeasy Micro 
Kit. Firstly, cells were washed three times with PBS and were resuspended with the 
350µl RLT solution. The cell lysate was then added into columns which were set in the 
collection tube. The tube was centrifuged (2min, 16000g) at room temperature (RT), 
and 350µl ethanol (70%) was added and well mixed. The mix was added into a clean 




flowthrough was discarded, and 350µl RW1 solution was added to the column. After 
another centrifugation (15s, 8000g, RT) and elimination of flowthrough, 80µl DNase I 
mix was pipetted into the column for incubation (15min, RT). After that, 350µl RW1 
solution was pipetted into the column, which was further centrifuged (15s, 8000g, RT). 
The column was rearranged into a new tube and was added with a 500µl RPE solution. 
After centrifugation (15s, 8000g, RT), the tube with flowthrough was discarded, and 
500µl 80% ethanol was added into the column. After another centrifugation (2min, 
8000g, RT) and rearrangement in a clean tube, the column was centrifugated again 
(5min, 16000g, RT). Subsequently, the column was rearranged in a new tube and was 
added with14µl RNase-free water. Following a 1min centrifugation (16000g, RT), RNA 
could be obtained and stored at -80°C. 
2.2.3.2 Reverse transcription and cDNA pre-amplification 
Reagents such as Quantiscript RT and RT Primer Mix should be maintained at RT 
before use, while RNA was kept in an icebox. The manufacturer's protocol was 
followed to remove the genomic DNA. Briefly, the tube including reagent mixture (1μL 
RNase-free water, 2μL Wipeout buffer, 11μL template RNA) was placed into 
Thermomixer at 42°C for 2min. The tube was then instantly put on ice. For reverse 
transcription, the tube was added with another mixture (1µl Quantiscript Reverse 
Transcriptase, 4µl Quantiscript RT Buffer, 1µl RT Primer Mix) for a 15min incubation at 
42°C. For transcriptase inactivation, the tube was incubated for 3 min at 95°C. 
Ultimately, cDNA could be achieved for further tests or maintained at -20°C. 
2.2.3.3 qRT-PCR procedure 
In our research, the fluorescence was detected using an intercalating reagent, SYBR 
Green I, which could fluoresce when bounding to the double-stranded DNA. The 




520nm. The target DNA could be quantitatively determined by assessing the 
fluorescence. The PCR cycles include one cycle for initial denaturation (95°C, 5min), 
40 cycles for primer hybridization (95°C, 10min) and elongation (60°C, 30min), and 
one cycle for melting (heating from 60 to 95°C in 6min). The fluorescence intensity was 
proportional to the PCR reaction, so it could be applied to assess the amount of the 
related nucleic acids. A threshold for the fluorescence intensity was established, and 
the threshold cycle (Ct) represented the cycle number when the fluorescence reached 
the threshold. For the relative quantification, the GAPDH gene was used as a reference. 
ΔCt represented the difference between CtGAPDH and Cttarget gene. The relative value of 
the target gene was computed with 2-ΔCt because DNA doubled with 100% amplification 
efficiency in every cycle. 
2.2.4 Enzyme-Linked ImmunoSorbent Assay (ELISA)  
The ELISA was conducted according to the manufacturer's protocol. To begin with, all 
reagents, working standards, and samples were prepared and kept at RT before the 
experiment. 100μL of Assay Diluent RD1-56 was added to each well. After that, each 
well was added with 50μL of standard, control, or sample and covered with the 
adhesive strip. The plate was incubated for 2h at RT on a horizontal orbital microplate 
shaker set at 500rpm. Each well was aspirated and washed with 400μL wash buffer, 
and this process was repeated three times for a total of four washes. The plate was 
inverted and blotted against clean paper towels. After that, each well was added with 
200μL of human thrombospondin-1 conjugate and covered with a new adhesive strip, 
followed by a 2h incubation at RT on the shaker. Then, the above aspiration/wash 
process was repeated, and 200μL of substrate solution was added to each well. The 
plate was subsequently incubated for 30min at RT in a dark room. 50 μL of stop solution 
was added to each well, and the color in the wells changed from blue to yellow. Finally, 




set at 450 nm, with the wavelength correction set at 540 nm. A standard curve was 
created using computer software, and the concentration of human THBS1 could be 
achieved then. 
2.2.5 Wound Healing (WH) Test 
For examination of PCCs migration, the standard protocol of WH assay was used. In 
brief, PCCs (5x105 cells/well) were seeded in 6-well plates in the incubator (37°C, 5% 
CO2/air, humid environment) until they reached 100% confluency. Cell monolayers 
were scratched with a tip (200μL) through every well. After being washed with PBS 
twice, PCCs were eliminated from cell fragments and were cultured under different 
conditions depending on the experiments. Images were captured at the time points of 
0h and 24h at 100x magnification. The wound area was analyzed with ImageJ and 
used for further statistical analysis.  
2.2.6 Transwell Migration and Invasion Assays 
The migration and invasion abilities of PCCs were examined by performing 
experiments using transwell chambers coated with or without Matrigel.  
Briefly, PCCs were cultivated using RPMI-1640 (1% FBS) for 24h. PCCs (5x104) were 
then suspended in 200μL FBS-free medium and added to the upper chamber, while 
600μL medium with different conditions depending on the experiments was added to 
the bottom chamber as a chemoattractant. The PCCs were allowed to migrate or 
invade for 24h and 48h, respectively. After that, PCCs on the upper surface of the 
membrane were removed with cotton swabs. PCCs on the lower side were then 
stained with 0.1% crystal violet at RT for 20min. Migratory and invasive cells were 
counted in five representative microscopy fields under a light microscope 




2.2.7 Western Blot 
2.2.7.1 Protein extraction 
To begin with, tissues were removed of adipose or connective parts, washed by PBS, 
and put into tubes. The tubes were then added with ice-cold lysis buffer rapidly, 
homogenized with a homogenizer, and maintained constant agitation for 2h at 4°C. 
Following centrifugation (20min, 12000rpm, 4°C), the tubes were placed on ice, and 
the supernatant was collected in new tubes and kept on ice. 
2.2.7.2 Protein quantitation 
The protein quantitation was conducted using the BCA Protein Assay Kit. According to 
the manufacturer's procedure, each well was filled with a 200µl reagent mixture 
(reagent A: B=50:1) and standard or target proteins (25µl). Afterward, the plate was 
maintained constant agitation for 30s at RT. After a 30min incubation at 37°C, the 
absorbance of the plate was measured at 562nm using a plate reader. The standard 
curve was achieved by plotting the relationship between the blank-adjusted average 
reading and the concentration (µg/mL).   
2.2.7.3 Western blotting 
2.2.7.3.1 Preparation of polyacrylamide gel  
Ethanol and DIW were used to clean the glass sheets and spacers. Clean glass plates 
and spacers were then assembled on a flat and horizontal platform. The glass plates 
with spacers were added with a 10mL resolving gel solution (Table 2). Isopropanol was 
overlaid above the resolving gel (20-30min, RT) to keep a horizontal surface. After the 
removal of isopropanol, the stacking gel solution (Table 2) was added until it overflowed. 




driven away manually. The gel was then left for 30min at RT for setting.  
2.2.7.3.2 Polyacrylamide gel electrophoresis (PAGE) 
Samples (containing equal volumes of proteins) and a weighted marker were gently 
added into SDS-PAGE wells. Running buffer (1x, Table 2) was poured into the 
electrophoresis apparatus. Afterward, the gel was run according to the manufacturer's 
protocol (100V, 1h). 
2.2.7.3.3 Membrane transfer 
PVDF membrane was activated with methanol for 25s. The membrane was then put 
into the transfer buffer before use (1x, Table 2). A rounded tweezer was used to deal 
with the membrane carefully to prevent scratches. Before the creation of the "transfer 
sandwich," filter papers and sponges were soaked in transfer buffer. After 
electrophoresis, the gel was isolated for the preparation of the sandwich. The sandwich 
layers were sequentially assembled, and any air bubbles should be removed gently 
with a tweezer as they could interfere with the transfer procedure. Finally, the sandwich 
was set in transfer equipment, and the wet transfer was performed according to the 
protocol. 
2.2.7.3.4 Immunoblotting 
After protein transfer, the membrane was washed with TBST (1x) solution 3 times. The 
membrane was then incubated overnight with blocking solution (Table 2) on a shaker 
(4˚C). Directed by the manufacturer's protocol, TBST (1x) solution containing 1% milk 
was used to make the primary Ab solution by diluting to working concentration. The 
membrane was then incubated in the primary Ab solution with gentle agitation (2h, RT). 




solution with gently shaking (1h, RT). After another three washes, the membrane was 
finally ready for further detection. 
2.2.7.3.5 Detection 
ECL substrate was made before use in accordance with the manufacturer's protocol. 
After a 3min incubation using ECL substrate, the membrane was exposed using a 
ChemiDoc MP imaging system (Bio-Rad). The grey values of the bands were 
measured by ImageJ software. 
Table 2 The formulas of different solutions in WB 
Solution Chemicals Doses 
Resolving gel solution 30% Acr  3.4mL 
 10% APS 100μL 
 DIW 3.8mL 
 10% SDS 100μL 
 TEMED 10μL 
 1.5M Tris-HCl (pH 8.8) 2.6mL 




 10% APS 100μL 
 DIW 5.86mL 
 10% SDS 100μL 
 1.5M Tris-HCl (pH 6.8) 2.6mL 
 TEMED 10μL 
Running Buffer (10x) DIW 1L 
 Gly 144g 
 SDS 10g 
 Tris Base 30g 
Running Buffer (1x) DIW 900μL 
 Running Buffer (10x) 100μL 
Transfer Buffer (10x) DIW 1L 




 Tris Base 30g 
Transfer Buffer (1x) DIW 800mL 
 Methanol 100mL 
 Transfer Buffer (10x) 100mL 
TBS (10x) DIW 1L 
 NaCl 80g 
 PH 7.6 
 Tris Base 24g 
TBST (1x) DIW 900mL 
 TBS (10x) 100mL 
 Tween 20 1mL 
Protein lysis Buffer Protease inhibitor 1 tablet 




Tris-HCl (1M) solution DIW 200mL 
 PH 6.8 
 Tris-base 12.12g 
Tris-HCl (1.5M) solution DIW 200mL 
 PH 8.8 
 Tris-base 36.34g 
Loading buffer loading buffer (4x) 900μL 
 β-Mercaptoethanol 100μL 
SDS solution (10%) DIW 100mL 
 SDS 10g 
APS solution (10%) APS 10g 
 DIW 100μL 




 TBST (1x) 20mL 
2.2.8 EZ4U Assay 
Cell proliferation was detected according to the manufacturer's protocol using an EZ4U 
kit. Briefly, cells (1x104 cells/well) were seeded in a 96-well plate utilizing 200μL RPMI-
1640 medium (10% FBS) per well. After 24h, the culture medium was refreshed by 
new medium with different treatments according to the experiments. After 48h culture, 
20μL dye substrate was added to every well and incubated for 3h. Finally, the 
absorbance of cells was determined using a microplate reader set at 450nm. 
2.2.9 Bioinformatic Analysis 
STRING database (https://string-db.org/) is a tool for analyzing the relationships 
(including physical and functional connections) between genes and establishing 
protein-protein interaction networks. Around 24 million proteins from 5,090 organisms 
were included in STRING (v11.0) [160]. In my project, papers on the differentially 
expressed genes in the activation procedure of PSCs were searched in PubMed. Then 
the protein-protein interaction networks among differentially expressed genes were 
analyzed using the STRING database.  
GEPIA (http://gepia.cancer-pku.cn/index.html) is a web-based tool for analyzing the 
RNA sequencing expression data, and it provides functions involving differential gene 
expression analysis, correlation analysis, patient survival analysis, and so on. Data of 
the tumor and paired normal samples from The Cancer Genome Atlas (TCGA: 
http://portal.gdc.cancer.gov/) and the Genotype-Tissue Expression (GTEx: 
http://gtexportal.org/home/) databases were included [161]. In my study, THBS1 and 




(n=179) matched with paired normal tissues (n=171), was investigated using GEPIA. 
The survival analysis of PDAC patients on THBS1 and CD47 was also conducted with 
this online tool.  
2.2.10 Statistical Analysis 
Statistical analysis was conducted utilizing SPSS 21.0. The standard deviation of the 
mean (SD) meant the variance of mean values. Student t-test was applied for 
comparisons between two groups. All results, if appropriate, in this project were 
described as the mean ± SD. Each experiment was performed at least three times in 













3.1 Prediction of THBS1 as a potential molecule regulated by 
VDR 
VDR activation by its ligand normalized PSCs, thereby decreasing PSCs-augmented 
malignancy of PCCs in co-culture. To investigate the downstream molecules which 
might function in this PSCs-PCCs crosstalk, I searched for related publications in 
PubMed and made a prediction via the STRING database (as shown in Materials & 
Methods). Two papers on the analysis of the differential gene expression in the 
activation procedure of PSCs were found [122, 162]. These genes were then employed 
to generate an evidence-based protein-interaction network in STRING, demonstrating 
the connections between several molecules with VDR in PSCs. By the prediction, 
THBS1, IL6, TGF-β1 were the candidates that might interact with VDR (Figure 4). IL6 
and TGF-β1 have been well investigated in the PSCs-PCCs crosstalk [94, 122, 163-
165]. Since THBS1 is an ECM protein widely expressed in tumor stroma and correlated 
with the aggressiveness of several other cancers [166-170], my study will further 





Figure 4: THBS1 was predicted as the potential protein interacting with VDR. Potential 
genes from Wehr et al. [162] (A) and Sherman et al. [122] (B) were employed to generate an 
evidence-based protein-interaction network in the STRING database, showing connections 





3.2 THBS1 and CD47 are overexpressed in PDAC and are 
correlated with poor survival 
To get a better understanding of the roles of THBS1 and its receptor CD47 in PDAC, I 
made bioinformatic analyses (see Materials & Methods 2.2.9) of THBS1, and CD47 
mRNA levels in 33 different types of cancers (n=15204), including PDAC (n=179), 
matched with paired normal tissues (n=171), with online server GEPIA which is based 
on the database of TCGA and GTEx [161].  
Compared with the adjacent normal group, THBS1 mRNA was significantly 
upregulated in the PDAC tumor group (Figure 5A-B). In addition, similar results were 
observed in CD47 at the mRNA level (Figure 6A-B).  
Furthermore, I studied the relationship between the clinical prognosis of PDAC patients 
and the mRNA expression levels of THBS1 and CD47. Results showed that mRNA 
expression of THBS1 or CD47 was negatively correlated with the disease-free survival 
of PDAC patients (p=0.036 and 0.018, respectively) (Figure 5C and 6C).  
These results showed that THBS1 and CD47 were dysregulated in PDAC and closely 
correlated with prognosis. Given the high expression of THBS1 in the stroma of many 
cancer, THBS1/CD47 axis might also play an essential role in the stroma-tumor 






Figure 5: Expression of THBS1 was higher in PDAC and reduced survival. THBS1 mRNA 
level: (A) in paired normal-tumor tissue cohort in 33 cancers. (B) in PDAC (n=179) and paired 
normal tissues (n=171). *p<0.05. (C) Kaplan-Meier analysis indicating the relationship between 







Figure 6: Expression of CD47 was higher in PDAC and reduced survival. CD47 mRNA 
level: (A) in paired normal-tumor tissue cohort in 33 cancers. (B) in PDAC (n=179) and paired 
normal tissues (n=171). *p<0.05. (C) Kaplan-Meier analysis indicating the relationship between 







3.3 CD47 protein is upregulated in PDAC  
Then I performed a western blot analysis to investigate the protein expression of CD47 
in PDAC. The result showed that the CD47 protein level was significantly higher in the 
tumor area of PDAC compared to the adjacent normal part (p=0.0222) (Figure 7). This 
further supported the results of the bioinformatic analysis above and indicated that 
CD47 could be an important receptor in PDAC development. 
 
Figure 7: CD47 protein expression in PDAC was higher than adjacent normal area. 
Western Blot analysis showed CD47 protein level was significantly higher in tumor part of PDAC 
than adjacent normal part (p=0.0222). GAPDH was utilized as the loading control. 





3.4 PSCs secret higher THBS1 than PCCs 
As reported in several cancers, THBS1 secretion rates by cancer-associated 
fibroblasts were at least one to two orders of magnitude higher than those by cancer 
cells [171-175]. However, no research was found on the THBS1 secretion by PSCs. 
Here, I detected THBS1 secretion in three different types of PSCs as well as three 
PDAC cell lines using ELISA. Results showed that all the three kinds of PSCs secreted 
significantly higher THBS1 than PCCs (p=0.0000, 0.0003, 0.0000), and the highest 
THBS1 secretion was observed in PSCs derived from the tumor (Figure 8).  
 
Figure 8: THBS1 secretion was higher in PSCs than PCCs. ELISA showed that PSCs, 
especially those derived from tumor, secreted higher THBS1 than PDAC cell lines (MIA PaCa-
2, PANC-1, AsPC-1). nPSCs: normal PSCs; cpPSCs: PSCs from chronic pancreatitis; caPSCs: 






3.5 The VD analog Cal decreases THBS1 secretion in PSCs 
Next, I examined the effect of a VD analog, Cal, on THBS1 secretion in PSCs using 
ELISA. The results showed that after being treated with 100nM Cal for 48h, THBS1 
protein levels in the supernatant of PSCs were significantly decreased compared to 
the control group (p=0.0000, 0.0018, 0.0026, respectively, Figure 9). This indicated 
that VDR induction by its ligand in PSCs could reduce the production of THBS1. This 
further demonstrated that THBS1 might be a critical molecular regulated by VDR and 
influence the PSCs-PCCs crosstalk. 
 
Figure 9: Cal decreased the THBS1 secretion in PSCs. ELISA was applied to test the change 
of THBS1 protein levels in the supernatant of PSCs from different origins after Cal treatment 
(100nM, 48h). VD analog was shown to decrease THBS1 secretion in all types of PSCs (n=3). 





3.6 The VD analog Cal diminishes PSCs-augmented PCCs 
proliferation, invasion, migration, and EMT by downregulating 
THBS1/CD47 axis 
As the results are shown above, PSCs secreted high THBS1, which could be inhibited 
by Cal. In addition, many studies have well proved that THBS1 can enhance the 
aggressiveness of several cancers [166-168, 176, 177]. Furthermore, our previous 
work indicated that the PSCs-augmented aggressiveness of PCCs in co-culture could 
be prevented by treating PSCs with Cal. Therefore, I proposed a hypothesis that Cal 
might downregulate PSCs-derived THBS1, thereby decreasing PCCs aggressiveness, 
and CD47 might mediate this process on PCCs. Here I further explored the role of the 
THBS1/CD47 axis in the PSCs-PCCs crosstalk. 
3.6.1 Recombinant THBS1 (rTHBS1) increases the proliferation, migration, 
invasion, and EMT morphology of PCCs 
Firstly, I investigated the effect of rTHBS1 on the proliferation ability of PCCs by EZ4U 
assay. Here I treated PCCs with different concentrations of rTHBS1 (0, 0.5, 5, 20μg/mL) 
and found that the proliferation abilities of both PANC-1 and MIA PaCa-2 were 
enhanced at 0.5μg/mL (p=0.0349, 0.0102 respectively), 5μg/mL (p=0.0053, 0.0006 
respectively) and 20μg/mL (p=0.0032, 0.0015 respectively). The results showed that 
rTHBS1 treatment significantly enhanced proliferation abilities of both PANC-1 and MIA 







Figure 10: rTHBS1 increased PCCs proliferation in a dose-dependent manner. After 
rTHBS1 treatment, the proliferation of both PANC-1 (left) and MIA PaCa-2 (right) was enhanced 
at 0.5μg/mL, 5μg/mL, and 20μg/mL compared to the control group. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001 
Then I explored the impact of rTHBS1 on the migration ability of PCCs via transwell 
migration assay and WH test. The results of the transwell migration assay showed that 
the treatment with rTHBS1 significantly increased the migration abilities of PANC-1 and 
MIA PaCa-2, both at 0.5 μg/mL (p=0.0125, 0.0083 respectively) and 5μg/mL (p=0.0000, 
0.0000 respectively) (Figure 11).  
 
Figure 11: rTHBS1 increased PCCs migration in a dose-dependent manner (transwell 
migration assay). Quantification analysis of transwell migration assay displayed the effect of 
rTHBS1 on the migration capabilities of PANC-1 (left) and MIA PaCa-2 (right). *p<0.05, 




I further conducted the WH test to confirm the effect of rTHBS1 on PCCs migration 
and found similar results. WH test showed that the migration rates of both PANC-1 and 
MIA PaCa-2 were significantly enhanced by the treatment of rTHBS1 at 0.5μg/mL (p= 
0.0162, 0.0083 respectively) and 5μg/mL (p=0.0033, 0.0005 respectively) (Figure 12). 
This result further confirmed that rTHBS1 treatment could enhance the migration 
abilities of PCCs in a dose-dependent manner. 
 
Figure 12: rTHBS1 increased PCCs migration in a dose-dependent manner (WH test). 
Representative images (left) and quantification analysis (right) of WH test displayed the effect 








Furthermore, I investigate the effect of rTHBS1 on PCCs invasion by transwell invasion 
assay. The result showed that rTHBS1 significantly increased the invasion abilities of 
PANC-1 and MIA PaCa-2 both at 0.5 μg/mL (p=0.0299, 0.0157 respectively) and 
5μg/mL (p=0.0040, 0.0010 respectively) (Figure 13). 
 
Figure 13: rTHBS1 increased PCCs invasion in a dose-dependent manner. Quantification 
analysis of transwell invasion assay exhibited the impact of rTHBS1 on the invasion abilities of 
PANC-1 (left) and MIA PaCa-2 (right). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
As well proved by several studies, PSCs could induce EMT procedure of PCCs [163, 
178-181]. Here I treated PCCs with PSCs-CM or rTHBS1. The result showed that after 
treatment with PSCs-CM or rTHBS1, PANC-1 and MIA PaCa-2 displayed typical 






Figure 14: EMT morphological changes of PCCs after PSCs-CM or rTHBS1 treatment. 
After being treated by PSCs-CM or rTHBS1, PANC-1 and MIA PaCa-2 exhibited a spindle-like 
appearance with less cell-cell adhesion. 
In conclusion, rTHBS1 increased the proliferation, migration, invasion abilities, as well 
as EMT morphology of PCCs.  
3.6.2 THBS1 neutralizing Ab inhibits PSCs-CM-induced proliferation, 
migration, invasion, and EMT of PCCs 
Furthermore, to determine whether Cal regulated the PSCs-induced aggressiveness 
of PCCs by modulating THBS1 expression, I used THBS1 neutralizing Ab to deplete 
THBS1 from CM of PSCs (PSCs-CM) or Cal-pretreated PSCs (Cal-PSCs-CM) and 
then cultured PCCs with the above CM. As shown in Figure 15, this treatment 
significantly decreased PSCs-CM-induced proliferation of PANC-1 and MIA PaCa-2 
(p=0.0133, 0.0106 respectively) but did not affect Cal-PSCs-CM-induced PCCs 
proliferation (p=0.3093, 0.5727 respectively).  
 
Figure 15: THBS1 neutralizing Ab inhibited PSCs-CM-induced PCCs proliferation. THBS1 
neutralizing Ab significantly diminished PSC-CM-induced PCCs proliferation but not Cal-PSCs-




Ab or control IgG. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
 
Then I conducted a transwell migration assay to confirm the THBS1 effect on the 
PSCs-induced migration ability of PCCs. The results showed that this treatment 
significantly diminished PSCs-CM-induced migration of PANC-1 and MIA PaCa-2 
(p=0.0000, 0.0000 respectively) but had no effect on Cal-PSCs-CM-induced PCCs 
migration (p=0.1077, 0.8075 respectively) (Figure 16). 
 
Figure 16: THBS1 neutralizing Ab inhibited the PSCs-CM-induced migration of PCCs 
(transwell migration assay). THBS1 neutralizing Ab significantly diminished PSCs-CM-
induced cancer cell migration but not Cal-PSCs-CM-induced PCCs migration. CM was 




*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
Furthermore, I performed the WH test to confirm the effect of THBS1 Ab on PSCs-
induced PCCs migration. The result showed that this treatment significantly decreased 
PSCs-CM-induced PCCs migration of PANC-1 and MIA PaCa-2 (p=0.0077, 0.0087 
respectively) but had no effect on Cal-PSCs-CM-induced PCCs migration (p=0.2624, 
0.2281 respectively) (Figure 17). 
 
Figure 17: THBS1 neutralizing Ab inhibited the PSCs-CM-induced migration of PCCs (WH 




not Cal-PSCs-CM-induced PCCs migration. CM was pretreated with 1μg/mL of THBS1 Ab or 
control IgG. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
In addition, I conducted a transwell invasion assay to explore the effect of THBS1 Ab 
on PSCs-induced PCCs invasion abilities. As shown in Figure 18, THBS1 Ab 
decreased PSCs-CM-induced invasion of PANC-1 and MIA PaCa-2 (p=0.0000, 0.0000 
respectively), while no impact was observed on Cal-PSCs-CM-induced PCCs invasion 
(p=0.3486, 0.2221 respectively). 
 
 
Figure 18: THBS1 neutralizing Ab inhibited the PSCs-CM-induced invasion of PCCs. 
THBS1 neutralizing Ab significantly diminished the PSCs-CM-augmented invasion of PCCs but 




control IgG and then added into the lower chambers. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
Finally, the EMT markers (E-cadherin, N-cadherin, Vimentin) were tested by qRT-PCR 
to explore the effect of THBS1 neutralizing Ab on PSCs-induced PCCs EMT. As shown 
in Figure 19, THBS1 Ab diminished PSCs-CM-induced EMT procedure in PCCs, while 
no impact was observed on Cal-PSCs-CM-induced PCCs. Specifically, the epithelial 
marker E-cadherin increased in PANC-1 and MIA PaCa-2 (p=0.0217, 0.0205 
respectively), while the mesenchymal markers N-cadherin (p=0.0068, 0.0151 
respectively) and Vimentin (p=0.0070, 0.0018 respectively) decreased. 
Figure 19: THBS1 neutralizing Ab inhibited the PSCs-CM-induced EMT procedure in 
PCCs. THBS1 neutralizing Ab significantly diminished the PSCs-CM-induced EMT procedure 
in PCCs but not the Cal-PSCs-CM-induced EMT in PCCs. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001 
In summary, these findings indicated that Cal decreased PSCs-augmented 




3.6.3 CD47 blocking Ab inhibits PSCs-CM-induced proliferation, migration, 
invasion, and EMT of PCCs 
Since THBS1 was reported to induce aggressiveness of tumor cells primarily by 
binding to CD47 in several cancers, I used a CD47 blocking Ab to investigate whether 
CD47 mediated the effect of THBS1 on PSCs-PCCs crosstalk or not.  
Firstly, results from the EZ4U assay indicated that blocking CD47 in PCCs significantly 
inhibited PSCs-CM-induced proliferation of PANC-1 and MIA PaCa-2 (p=0.0094, 
0.0019 respectively) but did not affect Cal-PSCs-CM-induced cell proliferation 
(p=0.5922, 0.4158 respectively) (Figure 20). These results showed that THBS1-
induced proliferation of PCCs was mediated by CD47. 
 
Figure 20: CD47 blocking Ab inhibited the PSCs-CM-induced proliferation of PCCs. CD47 
blocking Ab significantly reduced PSCs-CM-induced proliferation of PCCs but not Cal-PSCs-
CM-induced proliferation of PCCs. PCCs were pretreated with 2μg/mL of CD47 blocking Ab or 
control IgG. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
Transwell migration assay showed that this treatment significantly reduced the PSCs-
CM-induced migration of PANC-1 and MIA PaCa-2 (p=0.0002, 0.0000 respectively) 




respectively) (Figure 21). 
 
Figure 21: CD47 blocking Ab inhibited the PSCs-CM-induced migration of PCCs. CD47 
blocking Ab significantly decreased the PSCs-CM-induced migration of PCCs but not the Cal-









Furthermore, I conducted the WH test to validate the impact of CD47 Ab on the PSCs-
augmented migration of PCCs. The results also indicated that this treatment 
significantly diminished the PSCs-CM-induced migration of PANC-1 and MIA PaCa-2 
(p=0.0017, 0.0101 respectively) but had no effect on the Cal-PSCs-CM-induced 
migration of PCCs (p=0.3599, 0.4326 respectively) (Figure 22). 
 
Figure 22: CD47 blocking Ab inhibited the PSCs-CM-induced migration of PCCs (WH 
test). CD47 blocking Ab significantly diminished the PSC-CM-induced migration of PCCs but 





Additionally, I performed a transwell invasion assay to investigate the impact of CD47 
Ab on PSCs-induced invasion abilities of PCCs. As exhibited in Figure 23, CD47 Ab 
diminished the PSCs-CM-induced invasion of PANC-1 and MIA PaCa-2 (p=0.0000, 
0.0000 respectively), while no impact was observed on the Cal-PSCs-CM-induced 
invasion of PCCs (p=0.4977, 0.2005 respectively). 
 
Figure 23: CD47 blocking Ab inhibited PSCs-CM-induced invasion of PCCs. CD47 
blocking Ab significantly diminished the PSC-CM-induced invasion of PCCs but not the Cal-






Lastly, the EMT markers (E-cadherin, N-cadherin, Vimentin) were detected by qRT-
PCR to investigate the impact of CD47 blocking Ab on PSCs-augmented EMT 
procedure in PCCs. As exhibited in Figure 24, THBS1 Ab reduced PSCs-CM-induced 
EMT of PCCs, while no effect was observed on the Cal-PSCs-CM-induced EMT of 
PCCs. Specifically, the epithelial marker E-cadherin increased in PANC-1 and MIA 
PaCa-2 (p=0.0241, 0.0071 respectively), while the mesenchymal markers N-cadherin 
(p=0.0074, 0.0266 respectively) and Vimentin (p=0.0240, 0.0080 respectively) 
decreased. 
 
Figure 24: CD47 blocking Ab inhibited the PSCs-CM-induced EMT of PCCs. CD47 blocking 
Ab significantly diminished the PSCs-CM-induced EMT procedure of PCCs but not the Cal-
PSCs-CM-induced EMT of PCCs. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 
These results indicated that CD47 was involved in the PSCs-PCCs crosstalk, and 
CD47 blockade could reduce PSCs-augmented proliferation, invasion, migration, and 






4.1 VDR is a feasible target in PDAC treatment 
Accumulating evidence has shown that the VDR system plays a vital role in cancer 
development, and VD analogs have been evaluated in many preclinical experiments 
and clinical trials to treat different cancers.  
In our previous experiments conducted by Wu et al. [158], VDR expression of cancer-
associated PSCs was significantly higher than that of pancreatic cancer cell lines, 
which was similar to the results of Sherman et al. [122]. This demonstrates that VDR 
is a druggable target of PSCs and is of high potential in developing PDAC therapy. In 
addition, our group previously showed that the VD analog Cal could significantly 
decrease αSMA expression (an activation marker of PSCs), migration, and 
proliferation of PSCs using WB, qRT-PCR, ICC, wound healing test, transwell assay, 
and EZ4U [158]. This indicated that Cal could attenuate the activation of PSCs. 
Consistent results were also found in the published paper, which showed that VD 
analogs could decrease PSCs activation (reduced αSMA mRNA expression and 
increased lipid droplets formation) [122]. 
Similarly, Wallbaum et al. indicated that VD analog decreased protein expression of 
αSMA and inhibited loss of lipid droplets in murine PSCs [182]. Kang et al. invented a 
novel VD analog which could reduce αSMA protein expression and ECM deposition, 
thereby inhibiting fibrosis in mouse pancreas with chronic pancreatitis [183]. Blauer et 
al. showed that 1,25(OH)2D3 diminished proliferation and ECM production of murine 
PSCs [184]. Given the vital role of activated PSCs in the progression of PDAC, VDR 




It is well acknowledged that activated PSCs can enhance the malignancy of PCCs by 
various pathways. The strategy of simple depletion of PSCs has failed, which 
increased the malignancy of cancer cells, indicating the multifunctional role of PSCs in 
tumor development. Nowadays, reprogramming but not simply depleting PSCs has 
become a research hotspot. Therefore, many therapeutic strategies targeting PSCs 
for the treatment of PDAC have been proposed recently, such as vitamin A analogs, 
Ang-II inhibitors, SHH pathway inhibitors, and so on. 
Since our group previously revealed the role of Cal in normalizing PSCs, I further 
investigated the effects of Cal on the PSCs-augmented aggressiveness of PCCs, 
including proliferation, migration, invasion, and EMT. In my study, PCCs cultured with 
the conditioned medium from Cal-pretreated PSCs showed a diminished proliferation, 
migration, invasion, and EMT compared to the control group. This further confirmed 
the hypothesis that the VD analog Cal might deactivate PSCs, thereby hindering the 
PSCs-induced aggressiveness of PCCs. In addition, a recent study showed that drug 
combination (Cal+GEM) could reduce the tumor volume and increase survival in the 
mouse model of PDAC, compared to GEM treatment alone. Therefore, repurposing 
VD analogs is feasible in enhancing the treatment of PDAC by reprogramming PSCs.  
Several clinical trials are also found. A single application of VD analogs seems to be 
ineffective in the treatment of PDAC. Evans et al. indicated that EB1089 (a VD analog) 
had no anti-tumor effects on patients with inoperable PDAC [149]. Another VD analog, 
Arachitol, was evaluated by Barreto et al. in India. They demonstrated that 
intramuscular injection of Arachitol could not influence the overall morbidity and 
mortality rates of PDAC patients [150]. Nevertheless, drug combination with VD 
analogs and traditional chemotherapy drugs shows good prospects. Blanke et al. 
conducted a phase II trial to evaluate the drug combination (calcitriol+docetaxel) in 25 




fatigue) were observed, patients treated with this drug combination exhibited an 
increase in time to progression compared to those only treated with docetaxel [151]. 
More recently, another drug combination (nivolumab, cisplatin, nab-paclitaxel, 
paricalcitol, GEM) was evaluated in a phase II study (NCT02754726). Preliminary data 
from 24 patients were encouraging, showing that the objective response rate was 83%, 
with a median PFS of 8.17 months and a median OS of 15.3 months [152]. Several 
other clinical trials (NCT03472833, NCT03331562, NCT03520790, NCT03300921, 
NCT03883919, NCT03519308, NCT03415854) investigating the combination 
treatment of VD analogs and chemotherapy drugs are underway.  
Overall, targeting VDR is a promising therapeutic strategy to enhance conventional 
chemotherapy in PDAC as well as other stroma-rich tumors by remodeling stroma. It 
is also necessary to study the underlying mechanism (e.g., molecular pathways in the 
crosstalk), by which VD analogs reshape the PDAC microenvironment and inhibit the 











4.2 PSCs are vital sources of THBS1 in PDAC 
Since PSCs have been well proved to release numerous factors which increase the 
aggressiveness of PCCs [72, 80, 94, 142, 185-189], targeting the paracrine interaction 
between PSCs and PCCs has become a research hotspot recently.  
As VDR induction by its ligand has been shown to inhibit the PSCs-PCCs interaction, 
I further explored the molecules which might function in this procedure. By the STRING 
database analysis, I found that THBS1 might be a potential protein interacting with 
VDR and might play a role in the PSCs-enhanced malignancy of PCCs.  
THBS1 is a 450-kDa ECM protein rich in stroma. It is the first identified member in the 
family of thrombospondins and is a critical player in TME where it induces an 
aggressive tumor behavior, especially through interaction with the CD47 receptor in 
several cancers [190].  
Data of recent investigations have indicated that THBS1 was highly expressed in the 
stroma area of PDAC [191, 192]. Interestingly, several studies showed that THBS1 
secretion rates by fibroblasts were significantly higher than those by tumor cells in 
different cancers [171-175]. Detailed information can be found in Table 3. Since PDAC-
associated fibroblasts are mainly derived from PSCs, PSCs are mostly like the 
potential sources of THBS1 in PDAC. 
For the first time, I used ELISA to test THBS1 secretion in PSCs with different origins 
(normal, CP, and PDAC) as well as three pancreatic cancer cell lines. The results 
indicated that all kinds of PSCs secreted much higher THBS1 than PCCs. It is worth 
noting that tumor-derived PSCs showed the most elevated secretion of THBS1 among 
all the PSCs with different origins. Therefore, my result indicated that PSCs were the 




In addition, studies have shown that Vitamin D is closely related to THBS1. Adegoke 
et al. revealed an inverse relationship between serum 25-hydroxyvitamin D and THBS1 
in children with vaso-occlusive crisis [193]. Vitamin D supplementation was shown to 
markedly decrease THBS1 levels and blood pressure in healthy individuals [194]. In 
atherothrombosis research, Vitamin D analogs paricalcitol and calcitriol could 
downregulate mRNA and protein expression of THBS1 [195, 196]. Quiroz et al. 
indicated that Calcitriol could reduce THBS1 secretion in breast cancer cells[197]. 
However, few studies were found in PDAC research. In the current study, I treated 
different types of PSCs with Cal and found that this VD analog could significantly 
decrease the THBS1 secretion in PSCs.  
In summary, my results revealed that PSCs were essential sources of THBS1 secretion, 
and the VD analog Cal was able to reduce PSCs-derived THBS1. Given that THBS1 
has been proved to increase aggression in several cancers, the extremely high release 













Table 3 THBS1 secretion by human cancer cells and fibroblasts 
Cell types THBS1 secretion (ng/106 cells/24h) 
[reference]  
PDAC (AsPC-1, Colo-357, PANC-1, T3M4) 276; 61; 90; 94 [171] 
PDAC (AsPC-1, PANC-1, Mia PaCa-2) 103, 81, 78 (current study)  
Breast carcinoma (YMB-1)  3 [172] 
Lung carcinoma (A549)  20 [172] 
Gastric carcinoma (NUGC-4)  31 [172] 
Liver carcinoma (HLF) 89 [172] 
Colon carcinoma (Colo-201) 3 [172] 




Melanoma (DFB) 8 [172] 
Neuroblastoma (IMR-32) 4 [172] 
B-Chronic lymphocytic leukemia 9 [173] 
Foreskin fibroblast 474 [171]; 15700 [174]; 3333 [175] 
Fetal lung fibroblast 5800 [174] 
PSCs from normal pancreas 2771 (current study)  
PSCs from chronic pancreatitis 3438 (current study) 









4.3 THBS1 and CD47 are involved in the progression of PDAC 
Recent studies have shown that THBS1 plays an important role in cancer metastasis 
and aggressiveness. Pal et al. found that THBS1 increased the migration and invasion 
abilities of oral squamous cell carcinoma cells (OSCC) and induced the secretion of 
MMPs, thereby enhancing the malignancy of OSCC [198]. Borsotti et al. showed that 
THBS1 expression was higher in primary and metastases melanomas [170]. In another 
study, THBS1 promoted an aggressive behavior of tumor cells by inducing EMT in 
human melanoma [169]. Horiguchi et al. indicated that the expression of THBS1 was 
high in stromal components of invasive breast cancer and was positively correlated 
with enhanced lymph node metastasis [168]. In prostate cancer, high THBS1 
expression was found to be significantly associated with invasive tumors and tumor 
recurrence [167]. Huang et al. found that FGF7/FGFR2 could upregulate THBS1, 
thereby increasing the invasion and migration of gastric cancer [199]. An in-vivo study 
by Yee et al. indicated that THBS1 in TME enhanced lung metastasis in the transgenic 
mouse model of breast cancer [166]. Daubon et al. demonstrated that THBS1 
increased invasion via its receptor CD47 in tumor cells in glioblastoma [200]. Jeanne 
et al. utilized TAX2 to block the interaction between THBS1 and CD47, which inhibited 
metastasis and growth of melanoma cells in human malignant melanoma xenografts 
[201].  
In the field of pancreatic cancer, research on the THBS1/CD47 axis is still lacking. 
Okada et al. revealed that high stromal THBS1 expression was correlated with poor 
prognosis and invasiveness in intraductal papillary-mucinous neoplasm (the precursor 
lesions of PDAC) of the pancreas [202]. This indicated that THBS1 might play a 
significant role even in the initial stage of PDAC. With the online server GEPIA, I made 
the bioinformatic analyses and found that THBS1 and CD47 mRNA expression were 




addition, higher expression of THBS1 and CD47 was correlated with shorter disease-
free survival. Therefore, the THBS1/CD47 axis is most likely to participate in the 
progression of PDAC and deserves further study. 
Existing literature showed that THBS1 could enhance the invasion of PCCs in vitro 
[171, 203]. I performed a more detailed and comprehensive study to explore the effects 
of THBS1 on the aggressiveness of PCCs. In my research, recombinant THBS1 was 
shown to induce proliferation, migration, invasion, and EMT morphology changes of 
PCCs. This indicated that THBS1 was a key player in the tumor progression of PDAC. 
Combining my previous results that Cal could reduce the THBS1 secretion in PSCs, 
the ability of Cal to prevent PSCs-augmented malignancy of PCCs is probably 
mediated by downregulating PSCs-derived THBS1. 
However, no published studies thoroughly investigating the role of VDR/THBS1/CD47 
were found in PDAC research. Therefore, I used THBS1 neutralizing antibody and 
CD47 blocking antibody to explore further the role of THBS1/CD47 axis in PSCs-
augmented aggressiveness of PCCs. The outcomes showed that both THBS1 
neutralizing Ab and CD47 blocking Ab inhibited the PSCs-induced aggressiveness 
(proliferation, migration, invasion, EMT) of PCCs. This further confirmed the pro-
tumorigenic role of the THBS1/CD47 axis in PDAC. In addition, these effects were not 
observed in PCCs cultured with CM from Cal-deactivated PSCs, further indicating that 
Cal could downregulate the THBS1/CD47 axis in the PSCs-PCCs crosstalk. 
Combining the previous and current results of our group, I verified the hypothesis that 
the VD analog Cal could significantly reduce the activation, proliferation, migration of 
PSCs. The deactivated PSCs reduced the release of THBS1, thereby diminishing the 





4.4 The THBS1/CD47 axis is a promising target in PDAC 
treatment 
Since my results have indicated the critical role of the THBS1/CD47 axis in PDAC 
progression, targeting this axis is promising in developing an effective therapy for 
PDAC. 
Several studies have suggested the strategy of THBS1 depletion. Leca et al. found 
that depletion of THBS1-containing extracellular vesicles in CAFs reduced tumor 
growth and metastasis in PDAC mouse models [191]. Jeane et al. revealed that 
blockade of THBS1 with a newly designed peptide significantly inhibited the growth 
rate and vascularization of PDAC xenografts in nude mice [204]. In my study, depletion 
of PSCs-derived THBS1 markedly reduced the aggressiveness of PCCs in vitro. All 
these suggest that THBS1 is a key player in stroma-tumor interaction and targeting 
THBS1 is feasible in the development of PDAC therapy. 
The CD47 blockade strategy for PDAC has also been reported recently. Pan et al. 
revealed that CD47 blockade with a monoclonal antibody reduced the tumor burden in 
Panc02 tumor-bearing mice by increasing the pro-inflammatory macrophages, which 
exhibited anti-tumor function [205]. Golubovskaya et al. showed that CD47 blockade 
could reduce tumor growth in BxPC-3 tumor-bearing mice [206]. Cioffi et al. 
demonstrated that a combination of CD47 inhibition and chemotherapy drugs resulted 
in reduced tumor growth, long-term prevention of tumor recurrence after 
discontinuation of treatment in the patient-derived xenograft model [207]. My results 
also indicated that CD47 blockade could significantly reduce the PSCs-mediated pro-
tumorigenic effects on PCCs. Hence, CD47 is also a viable target for PDAC treatment. 




new research models which can replicate as much as possible the conditions inside 
human PDAC (e.g., hypoxia, high intratumoral pressure). In addition, since every 
model has its own limitations, it needs to be thoroughly assessed in different models 
before we take them into clinical trials.  
All in all, targeting the VDR/THBS1/CD47 axis is an effective therapeutic approach for 

















5. Conclusion and Outlook  
In summary, the VD analog Cal decreased PSCs-augmented proliferation, invasion, 
migration, and EMT of PCCs by downregulating THBS1, and this procedure was 
mediated by CD47. Figure 25 is a graphic summary of our project. Our work indicated 
that targeting VDR/THBS1/CD47 axis could be a promising strategy for PDAC therapy. 
In the future, we will further validate the outcomes, which may involve but is not limited 
to: a) confirming these results in the PDAC mouse model or organoid model. b) 
analyzing the correlation between VDR/THBS1/CD47 axis and clinical outcomes 
based on clinical data of PDAC patients in our hospital.  
 
Figure 25: Graphic summary of our work. VD analog could deactivate PSCs and decrease 






PDAC is a gastrointestinal malignancy with poor clinical outcomes. Accumulating 
evidence indicates that the crosstalk between PSCs and PCCs can establish a tumor-
supportive stroma of PDAC, thereby enhancing tumor growth, metastasis, and 
chemoresistance. Recently, targeting PSCs has emerged as a promising strategy for 
PDAC therapy since standard chemotherapy has shown disappointing outcomes. Our 
previous work has demonstrated that the VD analog Cal can deactivate PSCs as well 
as the PSCs-augmented malignancy of PCCs. This project aims to investigate the role 
of the VDR/THBS1/CD47 axis in PSCs-PCCs crosstalk in vitro, which would provide a 
new target therapy for PDAC treatment. 
Bioinformatic analysis showed that THBS1 and CD47 were highly expressed in PDAC 
and correlated with shorter disease-free survival. By ELISA, PSCs were shown to 
secret significantly higher expression of THBS1 than PCCs, and the VD analog Cal 
decreased THBS1 secretion in PSCs. PCCs treated with recombinant THBS1 
exhibited promoted proliferation, migration, invasion, and EMT of PCCs. Furthermore, 
THBS1 neutralizing Ab and CD47 blocking Ab were applied to investigate the role of 
the VDR/THBS1/CD47 axis in the PSCs-PCCs crosstalk. Results showed that both 
antibodies decreased the PSCs-induced malignancy of PCCs (proliferation, migration, 
invasion, and EMT) utilizing EZ4U, WH test, transwell assay, and qRT-PCR.  
In conclusion, Cal decreased PSCs-augmented proliferation, invasion, migration, and 
EMT of PCCs by downregulating THBS1, and this procedure was mediated by CD47. 
Our work indicated that targeting VDR/THBS1/CD47 axis could be a promising 





Das Pankreaskarzinom gilt als einer der bösartigsten Tumoren des 
Gastrointestinaltraktes und ist mit einer sehr schlechten Prognose vergesellschaftet. 
Es gilt hierbei als gesichert, dass das Tumorstroma ein wichtiger Mediator der 
Progression des Pankreaskarzinoms darstellt. Hierbei kommt es zu 
Wechselwirkungen zwischen den stromalen pankreatischen Stellatumzellen (PSCs) 
und den Pankreaskarzinomzellen (PCCs), wodurch das Tumorwachstum, die 
Metastasierung und die Chemoresistenz beeinflusst werden können. Die gezielte 
Behandlung dieser Stellatumzellen stellt somit eine vielversprechende Strategie zur 
Behandlung des Pankreaskarzinoms dar. In unseren Vorarbeiten konnten wir zeigen, 
dass Vitamin-D-Analoga die durch Stellatumzellen verstärkten Malignitätsmerkmale 
von Pankreaskarzinomuzellen verringern kann. Dieses Anschlussprojekt zielte darauf 
ab, die Rolle und das therapeutische Potential des Vitamin D Rezeptors, sowie des 
THBS1-CD47-Signalweges bei der Interaktion zwischen PSCs und PCCs in vitro zu 
untersuchen. 
In einer bioinformatischen Analyse der STRING Datenbank konnten wir zeigen, dass 
THBS1 und CD47 im Pankreaskarzinom deutlich überexprimiert werden und mit einem 
kürzeren krankheitsfreien Überleben korrelieren. In dieser Arbeit konnte die 
Überexpression von THBS1 mittels ELISA-Assay in Pankreaskarzinomzellen bestätigt 
und gezeigt werden, dass diese Vitamin-D abhängig ist. Die mit Vitamin-D Analogon 
behandelten Zellen zeigten eine verringerte THBS1 Sekretion. Darüber hinaus zeigte 
sich eine gesteigerte Proliferation, Migration, Invasion und EMT in PCCs nach 
Stimulation mit rekombinantem THBS1. Zuletzt konnte durch den Einsatz von sowohl 
THBS1 neutralisierenden Antikörpern als auch CD47-blockierenden Antikörpern die 
Stellatumzell-induzierten Malignitätsmerkmale von Pankreaskarzinomzellen 




Zusammenfassend lässt sich zeigen, dass die Stimulation der pankreatischen 
Stellatumzellen mit einem Vitamin-D Analogon über einer Herunterregulation von 
THBS1, vermittelt über den Rezeptor CD47, zu einer verminderten Proliferation, 
Invasion, Migration und EMT der Pankreaskarzinomzellen führt. Die vorliegende Arbeit 
demonstriert somit, dass die Vitamin-D-Rezeptor/THBS1/CD47-Achse ein 
vielversprechendes Ziel für eine zukünftige anti-tumorale Modulation des 
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